What is the recommended dose of Anti-Tetanus Serum (ATS) (Tetanus Immunoglobulin (TIG)) for tetanus post-exposure prophylaxis in an individual with unknown or no previous tetanus vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dose of Anti-Tetanus Serum (TIG) for Post-Exposure Prophylaxis

The recommended prophylactic dose of Tetanus Immunoglobulin (TIG) is 250 units intramuscularly for both adults and children with unknown or incomplete tetanus vaccination history who present with tetanus-prone wounds. 1, 2

When TIG is Actually Indicated

TIG is only required in specific circumstances—not for all wounds:

  • Administer TIG 250 units IM when the patient has received fewer than 3 lifetime doses of tetanus toxoid OR has unknown/uncertain vaccination history AND presents with any wound 1, 2

  • Do NOT administer TIG if the patient has completed a primary vaccination series (≥3 documented doses), regardless of how long ago the last dose was given, unless the patient is severely immunocompromised 1, 2

  • Severely immunocompromised patients (HIV infection, severe immunodeficiency) should receive TIG regardless of their tetanus immunization history when they have contaminated wounds 1, 2

Critical Administration Details

  • Always administer TIG and tetanus toxoid vaccine at separate anatomic sites using separate syringes to prevent interference with the immune response 1, 2

  • The 250-unit dose applies universally to both adult and pediatric patients—there is no weight-based dosing for prophylaxis 1

  • Human TIG is strongly preferred over equine antitoxin due to longer duration of protection (approximately 4 weeks versus 7-10 days) and significantly fewer adverse reactions 2, 3

Complete Wound Management Algorithm

For Patients with ≥3 Previous Doses:

  • Clean, minor wounds: Give tetanus toxoid (Tdap preferred if not previously received) only if ≥10 years since last dose; NO TIG needed 2

  • Contaminated/tetanus-prone wounds: Give tetanus toxoid (Tdap preferred if not previously received) only if ≥5 years since last dose; NO TIG needed 1, 2

For Patients with <3 Doses or Unknown History:

  • Any wound type: Give BOTH tetanus toxoid-containing vaccine (Tdap preferred) AND TIG 250 units IM at separate sites 1, 2

  • These patients must complete a full 3-dose primary vaccination series for long-term protection: second dose at ≥4 weeks, third dose at 6-12 months after the second 2

Tetanus-Prone Wound Classification

Wounds requiring the 5-year (rather than 10-year) interval for booster consideration include:

  • Puncture wounds and penetrating injuries (projectiles, crushing mechanisms) that create anaerobic environments 1
  • Wounds contaminated with dirt, soil, feces, or saliva 1, 2
  • Avulsions, burns, or other nonintact skin with potential contamination 1
  • Wounds with devitalized tissue 4

Special Populations and Supply Considerations

  • Elderly patients (≥60 years): Should be prioritized for TIG if supplies are limited, as 49-66% lack protective antibody levels 1, 2

  • Immigrants from regions outside North America/Europe: Should also be prioritized for TIG when supplies are limited, as they are less likely to have adequate vaccination history 1, 2

  • In mass-casualty settings with limited TIG supply, reserve TIG first for persons aged >60 years and immigrants from non-North American/European regions 1

Common Pitfalls to Avoid

  • Do not confuse the 10-year routine booster interval with the 5-year interval for contaminated wounds—this is the most common error in tetanus prophylaxis 2

  • Do not give TIG to patients with documented complete primary series unless they are severely immunocompromised—this wastes limited resources and provides no additional benefit 2

  • Do not assume vaccination history—patients with unknown or uncertain histories should be treated as having zero previous doses 2, 4

  • Research confirms that tetanus toxoid boosters do not produce protective antibody levels within the first 4 days after administration, even in previously vaccinated individuals, which validates the continued need for TIG in high-risk scenarios 5

Distinction from Treatment Dosing

The 250-unit prophylactic dose is dramatically different from the therapeutic dose used for active tetanus disease, which is 3,000-6,000 units—a 12-24 fold higher dose 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tetanus Vaccination for Nail Penetration Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Anti-tetanus vaccines, serums and immunoglobulins].

Bollettino dell'Istituto sieroterapico milanese, 1980

Guideline

Management of Established Tetanus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Tetanus Immunoglobulin Dosage for Active Tetanus Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended dose of tetanus immunoglobulin (TIG) for post-exposure prophylaxis?
Is another dose of tetanus toxoid (TT) needed for wound management if the patient received a dose 2 months ago?
What is the recommended schedule for the antitetanus toxoid (tetanus) vaccine?
Is it safe to administer Human Tetanus Immunoglobulin (HTIG) 250 IU a few days after tetanus toxoid in a patient with a recent abrasion wound and uncertain tetanus vaccination history?
Do I administer a tetanus (Td or Tdap) booster for an animal scratch if a tetanus shot was given 7 months ago?
How long after treatment for a perianal abscess with intravenous (IV) flucloxacillin and metronidazole, followed by oral antibiotics, should a patient follow up with their healthcare provider?
What is the proper usage and guidance for topical PUVA (psoralen and ultraviolet A) therapy, specifically the brand Oxsoralen Ultra (8-methoxypsoralen), in an infant or child with severe psoriasis or vitiligo?
What treatment options are available for a male patient with a history of fistulotomy, who now experiences tension and loss of sexual sensation without pain, which he attributes to guarding and being over-focused?
What is the recommended duration of oral antibiotics for a patient post-perianal abscess drainage?
Can a pediatric patient be exposed to narrowband ultraviolet B (nbUVB) phototherapy immediately after psoralen application?
What is the management approach for a 10-year-old child with probable appendicitis in the emergency medicine department?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.